Marinomed Biotech Past Earnings Performance
Past criteria checks 0/6
Marinomed Biotech has been growing earnings at an average annual rate of 15.1%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 13.5% per year.
Key information
15.1%
Earnings growth rate
19.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 13.5% |
| Return on equity | n/a |
| Net Margin | -104.0% |
| Next Earnings Update | 21 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Marinomed Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 7 | -7 | 5 | 0 |
| 31 Dec 23 | 9 | -7 | 5 | 0 |
| 30 Sep 23 | 11 | -6 | 5 | 0 |
| 30 Jun 23 | 12 | -6 | 5 | 0 |
| 31 Mar 23 | 12 | -7 | 5 | 0 |
| 31 Dec 22 | 11 | -6 | 5 | 0 |
| 30 Sep 22 | 13 | -5 | 5 | 0 |
| 30 Jun 22 | 13 | -5 | 5 | 0 |
| 31 Mar 22 | 12 | -6 | 5 | 0 |
| 31 Dec 21 | 12 | -6 | 5 | 0 |
| 30 Sep 21 | 9 | -8 | 5 | 0 |
| 30 Jun 21 | 9 | -7 | 5 | 0 |
| 31 Mar 21 | 9 | -7 | 5 | 0 |
| 31 Dec 20 | 8 | -6 | 4 | 0 |
| 30 Sep 20 | 8 | -6 | 4 | 0 |
| 30 Jun 20 | 7 | -6 | 4 | 0 |
| 31 Mar 20 | 7 | -6 | 4 | 0 |
| 31 Dec 19 | 7 | -7 | 4 | 0 |
| 30 Sep 19 | 5 | -14 | 4 | 0 |
| 30 Jun 19 | 5 | -15 | 3 | 0 |
| 31 Mar 19 | 5 | -14 | 3 | 0 |
| 31 Dec 18 | 5 | -12 | 3 | 0 |
| 30 Sep 18 | 6 | -4 | 2 | 0 |
| 31 Dec 17 | 5 | -2 | 2 | 0 |
| 31 Dec 16 | 4 | -2 | 2 | 0 |
| 31 Dec 15 | 3 | -1 | 2 | 0 |
Quality Earnings: 93Z is currently unprofitable.
Growing Profit Margin: 93Z is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 93Z is unprofitable, but has reduced losses over the past 5 years at a rate of 15.1% per year.
Accelerating Growth: Unable to compare 93Z's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 93Z is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 93Z's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.